Trial · NCT07084831
A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia
NCT07084831, Phase 3, Withdrawn, European Group for Research In Schizophrenia
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia. Trials, record NCT07084831. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07084831
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia
- NCT number
- NCT07084831
- Status
- Withdrawn
- Phases
- Phase 3
- Enrollment
- 0 participants, actual
- Lead sponsor
- European Group for Research In Schizophrenia
- Conditions
- Schizophrenia; Psychosis, Cognitive Impairment
- Interventions
- Xanomeline/trospium
- First posted
- 2025-07-25
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in cognitive performance after 24 weeks of treatment, relative to baseline. | 24 weeks | The within-participant change in the Brief Assessment of Cognition in Schizophrenia composite cognitive score from baseline to follow-up after 24 weeks. Higher score means better cognition. There is no max score, as the tests have different scoring methods (number correct, reaction time). |
| Secondary | Change in negative symptoms after 24 weeks of treatment, relative to baseline. | 24 weeks | The within-participant change in the Positive And Negative Syndrome Scale (PANSS) negative subscale from baseline to follow-up after 24 weeks. A higher score means more schizophrenia-related symptoms. The maximum score is 49. |
| Other | Change in Functional Skills assessment and training (FUNSAT) scores for ATM banking, ticket kiosk, and medication management after 12, 24 and 52 weeks of treatment, relative to baseline. | 12, 24 and 52 weeks | The within-participant change in the Functional Skills assessment and training (FUNSAT) scores for ATM banking, ticket kiosk and medication management from baseline to follow-up after 12, 24 and 52 weeks. Higher reaction time scores means worse functioning (without maximum), higher number correct means better functioning |
| Other | Change in Subjective Scale to Investigate Cognition in Schizophrenia (SSTICS) between baseline and week 24 | 24 weeks | The within-participant change in Subjective Scale to Investigate Cognition in Schizophrenia (SSTICS) between baseline and week 24. A higher score means better subjective and social cognition. |
| Other | Change in Subjective Scale to Investigate Social Cognition Scale scores (MRMET) between baseline and week 24 | 24 weeks | The within-participant change in Social Cognition Scale scores (MRMET) between baseline and week 24. A higher score means better subjective and social cognition. |
| Other | Change in Brief Assessment of Cognition in Schizophrenia (BACS) scores between baseline to week 12 and week 52. | Week 12 and 52 | The within-participant change in Brief Assessment of Cognition in Schizophrenia (BACS) scores between baseline to week 12 and week 52. Higher score means better cognition.There is no max score, as the tests have different scoring methods (number correct, reaction time). |
| Other | Change in the Positive And Negative Syndrome Scale (PANSS) Negative Subscale Factor from baseline to week 12 and week 52 | Week 12 and 52 | Within-participant change in the Positive And Negative Syndrome Scale (PANSS) Negative Subscale Factor from baseline to week 12 and week 52. A higher score means more schizophrenia-related symptoms. The maximum score is 49. |
| Other | Change in the Brief Negative Symptom Scale (BNSS) and Self-report of Negative Symptoms (SNS) scores from baseline to week 24 and week 52. | week 24 and 52 | Within-participant change in the Brief Negative Symptom Scale (BNSS) and Self-report of Negative Symptoms (SNS) scores from baseline to week 24 and week 52. A higher score on BNSS means more negative symptoms. The maximum score is 78. A higher score on SNS means more negative symptoms. The maximum score is 40. |
| Other | Change in the Positive And Negative Syndrome Scale (PANSS) Total and Positive Subscale scores from baseline to week 12; week 24 and week 52. | Week 12, 24 and 52 | Within-participant change in the Positive And Negative Syndrome Scale (PANSS)Total and Positive Subscale scores from baseline to week 12; week 24 and week 52. A higher score means more schizophrenia-related symptoms. The PANSS total score has a maximum of 210, while the positive scale has a maximum of 49. |
| Other | Change in safety assessments from baseline to week 4; week 12; week 24 and week 52 | week 4, 12, 24 and 52 | Within-participant change in safety assessments from baseline to week 4; week 12; week 24 and week 52. This is defined as the occurence of AEs during the study. The is no minimum or maximum. |
1 to 10 of 25Source ClinicalTrials.gov
See all 25 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07084831
GET https://conductscience.org/api/trials/v1/NCT07084831/registered?page=2